Toxin-mediated paracellular transport of antitoxin antibodies facilitates protection against Clostridium difficile infection

Infection and Immunity

Volumn 83, Issue 1, 2015, Pages 405-416

  Zhang, Z ^a   Chen, X ^b   Hernandez, L D ^a   Lipari, P ^a   Flattery, A ^a   Chen, S C ^a   Kramer, S ^a   Polishook, J D ^a   Racine, F ^a   Cape, H ^a   Kelly, C P ^b   Therien, A G ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTOXUMAB; ANTIBODY; ANTITOXIN ANTIBODY; BACTERIAL TOXIN; BEZLOTOXUMAB; FC RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; ANTITOXIN; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; ENTEROTOXIN; FC RECEPTOR, NEONATAL; HLA ANTIGEN CLASS 1; TCDA PROTEIN, CLOSTRIDIUM DIFFICILE; TOXB PROTEIN, CLOSTRIDIUM DIFFICILE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL TRANSPORT; CLOSTRIDIUM DIFFICILE INFECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; EPITHELIUM CELL; GENE DELETION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INTESTINE MUCOSA; MOUSE; NONHUMAN; TISSUE DISTRIBUTION; ANIMAL; C57BL MOUSE; CLOSTRIDIUM INFECTIONS; DEFICIENCY; DISEASE MODEL; FEMALE; IMMUNOLOGY; KNOCKOUT MOUSE; MALE; MESOCRICETUS; METABOLISM; ORGAN CULTURE TECHNIQUE; PASSIVE IMMUNIZATION; PEPTOCLOSTRIDIUM DIFFICILE;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, NEUTRALIZING; ANTITOXINS; BACTERIAL PROTEINS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DISEASE MODELS, ANIMAL; ENTEROTOXINS; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; MALE; MESOCRICETUS; MICE, INBRED C57BL; MICE, KNOCKOUT; ORGAN CULTURE TECHNIQUES; RECEPTORS, FC;

EID: 84919478422     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.02550-14     Document Type: Article

References (41)

1. Poutanen SM, Simor AE. 2004. Clostridium difficile-associated diarrhea in adults. CMAJ 171:51-58. http://dx.doi.org/10.1503/cmaj.1031189.
2. Rupnik M, Wilcox MH, Gerding DN. 2009. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 7:526-536. http://dx.doi.org/10.1038/nrmicro2164.
3. Jank T, Aktories K. 2008. Structure and mode of action of clostridial glucosylating toxins: the ABCD model. Trends Microbiol 16:222-229. http://dx.doi.org/10.1016/j.tim.2008.01.011.
4. Pruitt RN, Lacy DB. 2012. Toward a structural understanding of Clostridium difficile toxins A and B. Front Cell Infect Microbiol 2:28. http://dx.doi.org/10.3389/fcimb.2012.00028.
5. Voth DE, Ballard JD. 2005. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 18:247-263. http://dx.doi.org/10.1128/CMR.18.2.247-263.2005.
6. Papatheodorou P, Zamboglou C, Genisyuerek S, Guttenberg G, Aktories K. 2010. Clostridial glucosylating toxins enter cells via clathrin-mediated endocytosis. PLoS One 5:e10673. http://dx.doi.org/10.1371/journal.pone.0010673.
7. Schorch B, Song S, van Diemen FR, Bock HH, May P, Herz J, Brummelkamp TR, Papatheodorou P, Aktories K. 2014. LRP1 is a receptor for Clostridium perfringens TpeL toxin indicating a two-receptor model of clostridial glycosylating toxins. Proc Natl Acad Sci U S A 111:6431-6436. http://dx.doi.org/10.1073/pnas.1323790111.
8. Pfeifer G, Schirmer J, Leemhuis J, Busch C, Meyer DK, Aktories K, Barth H. 2003. Cellular uptake of Clostridium difficile toxin B. translocation of the N-terminal catalytic domain into the cytosol of eukaryotic cells. J Biol Chem 278: 44535-44541. http://dx.doi.org/10.1074/jbc.M307540200.
9. Qa'Dan M, Spyres LM, Ballard JD. 2000. pH-induced conformational changes in Clostridium difficile toxin B. Infect Immun 68:2470-2474. http://dx.doi.org/10.1128/IAI.68.5.2470-2474.2000.
10. Zhang Z, Park M, Tam J, Auger A, Beilhartz GL, Lacy DB, Melnyk RA. 2014. Translocation domain mutations affecting cellular toxicity identify the Clostridium difficile toxin B pore. Proc Natl Acad Sci U S A 111:3721-3726. http://dx.doi.org/10.1073/pnas.1400680111.
11. Hippenstiel S, Schmeck B, N'Guessan PD, Seybold J, Krull M, Preissner K, Eichel-Streiber CV, Suttorp N. 2002. Rho protein inactivation induced apoptosis of cultured human endothelial cells. Am J Physiol Lung Cell Mol Physiol 283:L830-L838. http://dx.doi.org/10.1152/ajplung.00467.2001.
12. Just I, Selzer J, Wilm M, von Eichel-Streiber C, Mann M, Aktories K. 1995. Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature 375:500-503. http://dx.doi.org/10.1038/375500a0.
13. Shen A. 2012. Clostridium difficile toxins: mediators of inflammation. J Innate Immun 4:149-158. http://dx.doi.org/10.1159/000332946.
14. Bassetti M, Villa G, Pecori D, Arzese A, Wilcox M. 2012. Epidemiology, diagnosis and treatment of Clostridium difficile infection. Expert Rev Anti Infect Ther 10:1405-1423. http://dx.doi.org/10.1586/eri.12.135.
15. Kyne L, Warny M, Qamar A, Kelly CP. 2000. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. NEngl J Med 342:390-397. http://dx.doi.org/10.1056/NEJM200002103420604.
16. Kyne L, Warny M, Qamar A, Kelly CP. 2001. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 357:189-193. http://dx.doi.org/10.1016/S0140-6736(00)03592-3.
17. Leav BA, Blair B, Leney M, Knauber M, Reilly C, Lowy I, Gerding DN, Kelly CP, Katchar K, Baxter R, Ambrosino D, Molrine D. 2010. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 28:965-969. http://dx.doi.org/10.1016/j.vaccine.2009.10.144.
18. Babcock GJ, Broering TJ, Hernandez HJ, Mandell RB, Donahue K, Boatright N, Stack AM, Lowy I, Graziano R, Molrine D, Ambrosino DM, Thomas WD, Jr. 2006. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun 74:6339-6347. http://dx.doi.org/10.1128/IAI.00982-06.
19. Ehrich M, Van Tassell RL, Libby JM, Wilkins TD. 1980. Production of Clostridium difficile antitoxin. Infect Immun 28:1041-1043.
20. Kink JA, Williams JA. 1998. Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun 66:2018-2025.
21. Steele J, Mukherjee J, Parry N, Tzipori S. 2013. Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease. J Infect Dis 207:323-330. http://dx.doi.org/10.1093/infdis/jis669.
22. Sun X, Wang H, Zhang Y, Chen K, Davis B, Feng H. 2011. Mouse relapse model of Clostridium difficile infection. Infect Immun 79:2856-2864. http://dx.doi.org/10.1128/IAI.01336-10.
23. Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, Nichol G, Thomas WD, Jr, Leney M, Sloan S, Hay CA, Ambrosino DM. 2010. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 362:197-205. http://dx.doi.org/10.1056/NEJMoa0907635.
24. Claypool SM, Dickinson BL, Yoshida M, Lencer WI, Blumberg RS. 2002. Functional reconstitution of human FcRn in Madin-Darby canine kidney cells requires co-expressed human beta 2-microglobulin. J Biol Chem 277:28038-28050. http://dx.doi.org/10.1074/jbc.M202367200.
25. Dickinson BL, Badizadegan K, Wu Z, Ahouse JC, Zhu X, Simister NE, Blumberg RS, Lencer WI. 1999. Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. J Clin Invest 104:903-911. http://dx.doi.org/10.1172/JCI6968.
26. Ben Suleiman Y, Yoshida M, Nishiumi S, Tanaka H, Mimura T, Nobutani K, Yamamoto K, Takenaka M, Aoganghua A, Miki I, Ota H, Takahashi S, Matsui H, Nakamura M, Blumberg RS, Azuma T. 2012. Neonatal Fc receptor for IgG (FcRn) expressed in the gastric epithelium regulates bacterial infection in mice. Mucosal Immunol 5:87-98. http://dx.doi.org/10.1038/mi.2011.53.
27. Yoshida M, Kobayashi K, Kuo TT, Bry L, Glickman JN, Claypool SM, Kaser A, Nagaishi T, Higgins DE, Mizoguchi E, Wakatsuki Y, Roopenian DC, Mizoguchi A, Lencer WI, Blumberg RS. 2006. Neonatal Fc receptor for IgG regulates mucosal immune responses to luminal bacteria. J Clin Invest 116:2142-2151. http://dx.doi.org/10.1172/JCI27821.
28. Chen X, Katchar K, Goldsmith JD, Nanthakumar N, Cheknis A, Gerding DN, Kelly CP. 2008. A mouse model of Clostridium difficileassociated disease. Gastroenterology 135:1984-1992. http://dx.doi.org/10.1053/j.gastro.2008.09.002.
29. Yoshida M, Claypool SM, Wagner JS, Mizoguchi E, Mizoguchi A, Roopenian DC, Lencer WI, Blumberg RS. 2004. Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity 20:769-783. http://dx.doi.org/10.1016/j.immuni.2004.05.007.
30. Du T, Alfa MJ. 2004. Translocation of Clostridium difficile toxin B across polarized Caco-2 cell monolayers is enhanced by toxin A. Can J Infect Dis 15:83-88.
31. Nusrat A, von Eichel-Streiber C, Turner JR, Verkade P, Madara JL, Parkos CA. 2001. Clostridium difficile toxins disrupt epithelial barrier function by altering membrane microdomain localization of tight junction proteins. Infect Immun 69:1329-1336. http://dx.doi.org/10.1128/IAI.69.3.1329-1336.2001.
32. Sambuy Y, De Angelis I, Ranaldi G, Scarino ML, Stammati A, Zucco F. 2005. The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics. Cell Biol Toxicol 21:1-26. http://dx.doi.org/10.1007/s10565-005-0085-6.
33. Sutton PA, Li S, Webb J, Solomon K, Brazier J, Mahida YR. 2008. Essential role of toxin A in C. difficile 027 and reference strain supernatant-mediated disruption of Caco-2 intestinal epithelial barrier function. Clin Exp Immunol 153:439-447. http://dx.doi.org/10.1111/j.1365-2249.2008.03690.x.
34. Orth P, Xiao L, Hernandez LD, Reichert P, Sheth PR, Beaumont M, Yang X, Murgolo N, Ermakov G, DiNunzio E, Racine F, Karczewski J, Secore S, Ingram RN, Mayhood T, Strickland C, Therien AG. 2014. Mechanism of action and epitopes of Clostridium difficile toxin B-neutralizing antibody bezlotoxumab revealed by X-ray crystallography. J Biol Chem 289:18008-18021. http://dx.doi.org/10.1074/jbc.M114.560748.
35. Blikslager AT, Moeser AJ, Gookin JL, Jones SL, Odle J. 2007. Restoration of barrier function in injured intestinal mucosa. Physiol Rev 87:545-564. http://dx.doi.org/10.1152/physrev.00012.2006.
36. Pasetti MF, Simon JK, Sztein MB, Levine MM. 2011. Immunology of gut mucosal vaccines. Immunol Rev 239:125-148. http://dx.doi.org/10.1111/j.1600-065X.2010.00970.x.
37. Roopenian DC, Akilesh S. 2007. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7:715-725. http://dx.doi.org/10.1038/nri2155.
38. Johnston PF, Gerding DN, Knight KL. 2014. Protection from Clostridium difficile infection in CD4 T cell-and polymeric immunoglobulin receptor-deficient mice. Infect Immun 82:522-531. http://dx.doi.org/10.1128/IAI.01273-13.
39. Hamm EE, Voth DE, Ballard JD. 2006. Identification of Clostridium difficile toxin B cardiotoxicity using a zebrafish embryo model of intoxication. Proc Natl Acad Sci U S A 103:14176-14181. http://dx.doi.org/10.1073/pnas.0604725103.
40. Steele J, Chen K, Sun X, Zhang Y, Wang H, Tzipori S, Feng H. 2012. Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models. J Infect Dis 205:384-391. http://dx.doi.org/10.1093/infdis/jir748.
41. Berkes J, Viswanathan VK, Savkovic SD, Hecht G. 2003. Intestinal epithelial responses to enteric pathogens: effects on the tight junction barrier, ion transport, and inflammation. Gut 52:439-451. http://dx.doi.org/10.1136/gut.52.3.439.